Advances of research on the function of RNA binding proteins in the pathogenesis of thyroid carcinoma

doi:10.16352/j.issn.1001-6325.2022.08.1306

Abstract

Abstract: RNA-binding protein (RBP) plays an important role in the pathogenesis of thyroid cancer. It can regulate the intracellular activities such as transcription, nuclear output, alternative splicing and translation of mRNA from tumor-related genes at the post-transcriptional or translation levels, and then regulate the proliferation, apoptosis and migration of thyroid cancer, thereby promoting or inhibiting the occurrence of tumors. Clinically, a series of RBP molecules are significantly correlated with the classification and prognosis of patients with thyroid cancer and may support the oncological classification, evaluation and prediction of prognosis of thyroid cancer.

Key words: RNA-binding protein, thyroid carcinoma, tumor growth

CLC Number:

R737.9

ZHOU Mei-cen, LAN Ling, DENG Wei. Advances of research on the function of RNA binding proteins in the pathogenesis of thyroid carcinoma[J]. Basic & Clinical Medicine, 2022, 42(8): 1306-1309.

References 25

[1]	Castello A, Fischer B, Eichelbaum K, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins[J]. Cell, 2012,49:1393-1406.
[2]	Jonas K, Calin GA, Pichler M.RNA-binding proteins as important regulators of long non-coding RNAs in cancer[J].Int J Mol Sci, 2020,21:2969.doi:10.3390/ijms21082969.
[3]	Wu M, Tong CWS, Yan W, et al. The RNA binding protein HuR:a promising drug target for anticancer therapy[J]. Curr Cancer Drug Targets, 2019,19:382-399.
[4]	Du LB,Li RH, Ge MH,et al. Incidence and mortality of thyroid cancer in China, 2008—2012[J]. Chin J Cancer Res,2019,31:144-151.
[5]	Allegri L, Mio C, Russo D, et al. Efects of HuR downregulation on anaplastic thyroid cancer cells[J]. Oncol let, 2018, 15:575-579.
[6]	Wang Y, He H, Liyanarachchi S, et al. The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma[J]. Genet Med,2018, 20:927-935.
[7]	Zhang MP, Zhang WS, Tan J, et al. Poly r(C) binding protein (PCBP) 1 expression is regulated by the E3 ligase UBE4A in thyroid carcinoma[J]. Biosci Rep,2017, 37.doi:10.1042/BSR20170114.
[8]	Giaginis C, Alexandrou P, Delladetsima I, et al. Clinical Significance of Hu-Antigen Receptor (HuR) and Cyclooxygenase-2 (COX-2) Expression in Human Malignant and Benign Thyroid Lesions[J]. Pathol Oncol Res, 2016, 22:189-196.
[9]	Allegri L, Baldan F, Roy S. The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells[J]. Sci Rep, 2019,9:7374.doi:10.1038/s41598-019-43894-0.
[10]	Allegri L, Mio C, Russo D, et al. Effects of HuR downregulation on anaplastic thyroid cancer cells[J]. Oncol Lett, 2018,15:575-579.
[11]	Trojanowicz B, Brodauf L, Sekulla C,et al. The role of AUF1 in thyroid carcinoma progression[J]. Endocr Relat Cancer,2009,16:857-871.
[12]	Trojanowicz B, Sekulla C, Dralle H, et al.Expression of ARE-binding proteins AUF1 and HuR in follicular adenoma and carcinoma of thyroid gland[J]. Neoplasma,2016;63:371-377.
[13]	Donati B, Ciarrocchi A. Telomerase and telomeres biology in thyroid cancer[J]. Int J Mol Sci, 2019, 20:2887.doi:10.3390/ijms20122887.
[14]	Yuan XT, Catharina L, Xu DW. Mechanisms underlying the activation of TERT transcription and telomer-ase activity in human cancer:old actors and new players[J]. Oncogene, 2019,38:6172-6183.
[15]	Colebatch JA, Dobrovic A, Cooper AW. TERT gene:its function and dysregulation in cancer[J]. J Clin Pathol, 2019, 72:281-284.
[16]	Jin AQ, Xu JH, Wang Y. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer[J]. Medicine (Baltimore), 2018,97:e11548,doi:10.1097/MD,0000000000011548.
[17]	Panebianco F, Nikitski AV, Nikiforova MN,et al. Spec-trum of TERT promoter mutations and mechanisms of activation in thyroid cancer[J]. Cancer, 2019,8:5831-5839.
[18]	Chung JH.BRAF and TERT promoter mutations:clinical application in thyroid cancer[J].Endocr J, 2020,67:577-584.
[19]	Chara C, Sarah B. The La-related proteins, a family with connections to cancer[J]. Biomolecules, 2015,5:2701-2722.
[20]	Sui XM, Sui YN, Wang YH. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway[J]. Mol Med Rep,2018,17:7521-7528.
[21]	Zhang XT, Di CX, Chen YH,et al. Multilevel regulation and molecular mechanism of poly (rC)-binding protein 1 in cancer[J]. FASEB J, 2020. doi:10.1096/fj.202000911R.
[22]	Guo J, Jia R.Splicing factor poly(rC)-binding protein 1 is a novel and distinctive tumor suppressor[J]. J Cell Physiol, 2018,234:33-41.
[23]	Zhang X, Di C, Chen Y, et al. Multilevel regulation and molecular mechanism of poly (rC)-binding protein 1 in cancer[J].FASEB J, 2020,34:15647-15658.
[24]	Wang YQ, He HL, Liyanarachchi S,et al. The role of SMAD3 in the genetic predisposition to papillary thyroid carcinoma[J]. Genet Med, 2018,20:927-935.
[25]	Gulius J, Gudmar T, Kjons S,et al. A genome-wide association study yields five novel thyroid cancer risk loci[J]. Nat Commun, 2017,14,8:14517. doi:10.1038/ncomms14517.